Foreword |
|
xi | |
|
|
|
xv | |
|
|
3 | (6) |
|
|
|
|
5 | (4) |
|
2 An Integrated Framework for Human Neuroimaging Studies of Addiction from a Preclinical Perspective |
|
|
9 | (30) |
|
|
|
|
9 | (1) |
|
2.2 A Conceptual Framework for Understanding Drug Addiction Based on Preclinical Observations |
|
|
9 | (6) |
|
2.3 Neuropharmacological Considerations |
|
|
15 | (1) |
|
2.4 Neuropathology of Chronic Drug Abuse |
|
|
15 | (2) |
|
2.5 Impulsivity: An Endophenotype for Drug Addiction |
|
|
17 | (3) |
|
2.6 Compulsivity: Craving versus Drug-Seeking |
|
|
20 | (5) |
|
|
25 | (14) |
|
|
26 | (13) |
|
3 Structural and Functional Neuroimaging Methods: Applications to Substance Abuse and Addiction |
|
|
39 | (46) |
|
|
|
|
|
|
|
|
39 | (1) |
|
3.2 MRI Based Imaging Tools and their Application to Drug Abuse Research |
|
|
40 | (19) |
|
3.3 Molecular Imaging with PET and SPECT |
|
|
59 | (10) |
|
3.4 Summary and Peek into the Future |
|
|
69 | (16) |
|
|
69 | (16) |
|
4 Functional Neuroimaging of the Acute Effects of Drugs of Abuse |
|
|
4 | (103) |
|
|
|
|
85 | (1) |
|
4.2 Fundamental Neuronal Systems Related to Abuse Liability in Humans |
|
|
86 | (1) |
|
|
87 | (5) |
|
|
92 | (3) |
|
4.5 Cannabis and the Cannabinoids |
|
|
95 | (1) |
|
|
96 | (2) |
|
4.7 Conclusions and Future Directions |
|
|
98 | (9) |
|
|
99 | (8) |
|
|
107 | (26) |
|
|
|
|
|
107 | (1) |
|
5.2 Neurotransmitter Systems Implicated in Reward Processing |
|
|
107 | (3) |
|
5.3 Neurotransmitter Systems Involved in Drug-Related Reward Processing |
|
|
110 | (6) |
|
5.4 Alterations in the Mesostriatal System in Addiction |
|
|
116 | (6) |
|
|
122 | (1) |
|
|
123 | (10) |
|
|
123 | (10) |
|
6 A Neuroimaging Approach to the Study of Craving |
|
|
133 | (26) |
|
|
|
|
6.1 A Neuroimaging Approach to the Study of Craving |
|
|
133 | (1) |
|
6.2 Neural Response During Cue-Elicited Craving |
|
|
134 | (7) |
|
6.3 Associations between Neural and Subjective Response During Cue-Elicited Craving |
|
|
141 | (1) |
|
6.4 Modulators of Neural Response During Cue-Elicited Craving |
|
|
142 | (5) |
|
6.5 Effects of Intervention on the Neural Response During Cue-Elicited Craving |
|
|
147 | (2) |
|
6.6 Summary and Integration of Findings |
|
|
149 | (2) |
|
|
151 | (8) |
|
|
151 | (8) |
|
7 Impulsivity and Addiction |
|
|
159 | (20) |
|
|
|
159 | (1) |
|
7.2 Impulsivity as Reward versus Control |
|
|
159 | (2) |
|
7.3 The Neurobiology of Impulsivity |
|
|
161 | (2) |
|
7.4 Impulsivity and Risk for Developing a Drug Use Disorder |
|
|
163 | (2) |
|
7.5 Impulsivity in Current Users |
|
|
165 | (3) |
|
7.6 Impulsivity, Abstinence, and Relapse |
|
|
168 | (2) |
|
|
170 | (9) |
|
|
171 | (8) |
|
8 Cognitive Disruptions in Drug Addiction: a Focus on the Prefrontal Cortex |
|
|
179 | (32) |
|
|
|
|
|
179 | (2) |
|
|
181 | (9) |
|
|
190 | (3) |
|
|
193 | (5) |
|
8.5 Pre-Morbid Vulnerabilities |
|
|
198 | (1) |
|
|
198 | (1) |
|
8.7 Limitations Across ALL Studies |
|
|
199 | (1) |
|
8.8 Treatment Implications |
|
|
200 | (1) |
|
8.9 GeneraL Summary and Conclusions |
|
|
200 | (1) |
|
|
201 | (10) |
|
|
201 | (10) |
|
9 Neural Mechanisms of Stress and Addiction |
|
|
211 | (26) |
|
|
|
|
211 | (1) |
|
9.2 Neural Circuits of Stress Regulation |
|
|
212 | (6) |
|
9.3 Dysfunction in the Neural Circuits Underlying Stress and Addiction |
|
|
218 | (4) |
|
9.4 Interplay of Gene, Stress, and Drug Intake |
|
|
222 | (2) |
|
|
224 | (13) |
|
|
224 | (13) |
|
10 Anatomical and Neurochemical Evidence of Neurotoxic Changes in Psychostimulant Abuse and Dependence |
|
|
237 | (26) |
|
|
|
|
237 | (1) |
|
10.2 Characteristics of Psychostimulants |
|
|
238 | (1) |
|
10.3 Quantitative MR Morphology Changes Associated with Psychostimulant Dependence |
|
|
239 | (1) |
|
10.4 Gross Anatomic Changes in Brain Structures and Subtle Neurotoxicity |
|
|
240 | (1) |
|
10.5 Relationship between Errant Neuromodulation by Drug Abuse and Cognitive Abnormalities |
|
|
241 | (3) |
|
10.6 Neurochemical Alterations and Psychostimulant Dependence |
|
|
244 | (5) |
|
10.7 Abnormal White Matter Integrity in Psychostimulant Dependence |
|
|
249 | (2) |
|
10.8 Alcohol and Opiate Addiction |
|
|
251 | (1) |
|
|
252 | (11) |
|
|
253 | (10) |
|
11 Neuroimaging in Behavioral Addictions |
|
|
263 | (24) |
|
|
|
|
263 | (1) |
|
11.2 Diagnostic Considerations |
|
|
264 | (1) |
|
11.3 Mesostriatal Dopamine Pathway |
|
|
265 | (4) |
|
|
269 | (4) |
|
|
273 | (4) |
|
|
277 | (10) |
|
|
279 | (8) |
|
12 Imaging Genetics and Addiction |
|
|
287 | (34) |
|
|
|
|
287 | (2) |
|
12.2 Domains of Vulnerability |
|
|
289 | (11) |
|
|
300 | (1) |
|
12.4 Brain Morphometric Changes |
|
|
301 | (1) |
|
|
302 | (2) |
|
12.6 Imaging Pharmacogenetics |
|
|
304 | (2) |
|
|
306 | (15) |
|
|
308 | (1) |
|
|
309 | (12) |
|
13 The Diagnostic and Therapeutic Potential of Neuroimaging in Addiction Medicine |
|
|
321 | (24) |
|
|
|
13.1 Can fMRI Become the ECG in Addiction Medicine, or What Are the Treatment Implications of Neuroimaging Research in Drug Addiction? |
|
|
321 | (1) |
|
13.2 Functional Neuroimaging in Addiction: Relevant Cognitive Constructs to Address during Treatment |
|
|
322 | (3) |
|
13.3 Drug Challenge Studies Enhance Knowledge on Pharmacokinetics and Drug-Experience-Relationships |
|
|
325 | (1) |
|
13.4 Imaging Symptom Severity |
|
|
325 | (1) |
|
13.5 Neuroimaging-Based Monitoring of Treatment Regimes and the Prediction of Treatment Outcomes |
|
|
326 | (3) |
|
13.6 Assessing the Relapse Potential Using fMRI |
|
|
329 | (5) |
|
13.7 Neurofeedback as a Therapeutic Approach? |
|
|
334 | (1) |
|
13.8 Methodological Challenges to Utilize Functional Neuroimaging as a Clinical Test |
|
|
335 | (1) |
|
13.9 The Near Future of Brain Imaging in Addiction Medicine |
|
|
336 | (9) |
|
|
338 | (7) |
Index |
|
345 | |